PPARG and liposarcoma: This small pilot trial of sixsubjects demonstrated a differentiating effect of short-term troglitazonetherapy in advanced stage liposarcomas providing the rationale for furtherclinical evaluation of troglitazone and other PPARγ ligands in the managementof liposarcomas.